Histone deacetylase inhibitors in programmed cell death and cancer therapy
- PMID: 15738652
- DOI: 10.4161/cc.4.4.1564
Histone deacetylase inhibitors in programmed cell death and cancer therapy
Abstract
Histone deacetylase (HDAC) inhibitors, such as suberoylanilide hydroxamic acid (SAHA), are targeted anticancer agents that have significant anticancer activity at doses well tolerated by patients. Recently, we found that HDAC inhibitors can trigger both mitochondria-mediated apoptosis and caspase-independent autophagic cell death, indicating potential benefit of HDAC inhibitors in treating cancers with apoptotic defects. We also found that thioredoxin (TRX) might play a significant role in HDAC inhibitor-induced cell death, and HDAC inhibitors increase TRX levels in normal cells but not transformed cells, which is likely to be one of the reasons why HDAC inhibitors preferentially kill cancer cells. In this review, we discuss the study of HDAC inhibitors in cell death and cancer research, the implications of our recent findings, and some outstanding questions that need to be addressed.
Similar articles
-
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors.Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18030-5. doi: 10.1073/pnas.0408345102. Epub 2004 Dec 13. Proc Natl Acad Sci U S A. 2004. PMID: 15596714 Free PMC article.
-
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):673-8. doi: 10.1073/pnas.0408732102. Epub 2005 Jan 6. Proc Natl Acad Sci U S A. 2005. PMID: 15637150 Free PMC article.
-
Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.Oncotarget. 2017 Mar 14;8(11):17726-17737. doi: 10.18632/oncotarget.14628. Oncotarget. 2017. PMID: 28099148 Free PMC article.
-
Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.J Natl Cancer Inst. 2000 Aug 2;92(15):1210-6. doi: 10.1093/jnci/92.15.1210. J Natl Cancer Inst. 2000. PMID: 10922406 Review.
-
Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.Anticancer Drugs. 2010 Oct;21(9):805-13. doi: 10.1097/CAD.0b013e32833dad91. Anticancer Drugs. 2010. PMID: 20679890 Review.
Cited by
-
Loci specific epigenetic drug sensitivity.Nucleic Acids Res. 2020 May 21;48(9):4797-4810. doi: 10.1093/nar/gkaa210. Nucleic Acids Res. 2020. PMID: 32246716 Free PMC article.
-
HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs.Oncotarget. 2022 Oct 14;13:1122-1135. doi: 10.18632/oncotarget.28278. Oncotarget. 2022. PMID: 36243940 Free PMC article.
-
Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat.Biologics. 2007 Dec;1(4):377-92. Biologics. 2007. PMID: 19707308 Free PMC article.
-
Deacetylase inhibitors - focus on non-histone targets and effects.World J Biol Chem. 2010 May 26;1(5):55-61. doi: 10.4331/wjbc.v1.i5.55. World J Biol Chem. 2010. PMID: 21540990 Free PMC article.
-
Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.Haematologica. 2010 Apr;95(4):613-21. doi: 10.3324/haematol.2009.013870. Epub 2010 Feb 4. Haematologica. 2010. PMID: 20133897 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
